Chromosomal instability (CIN) is commonly observed in human solid tumours, with the apparent gain or loss of large parts or whole chromosomes, leading to DNA aneuploidy ([Lengauer *et al*, 1997](#bib20){ref-type="other"}; [Duesberg *et al*, 1999](#bib7){ref-type="other"}). In previous studies, CIN has been associated in some cases with alterations in the cell-cycle checkpoint that monitors the integrity of the spindle apparatus, a structure critical for proper bipolar segregation of duplicated sister chromatids at mitosis ([Cahill *et al*, 1999](#bib3){ref-type="other"}). A small fraction of CIN cancers are associated with dominant mutations in the human homologues of yeast spindle checkpoint genes *BUB1* ([Cahill *et al*, 1998](#bib4){ref-type="other"}; [Imai *et al*, 1999](#bib14){ref-type="other"}; [Gemma *et al*, 2000](#bib12){ref-type="other"}) and *MAD2* ([Li and Benezra, 1996](#bib21){ref-type="other"}; [Cahill *et al*, 1999](#bib3){ref-type="other"}). However, *BUB1* and *MAD2* mutations are relatively rare, and gastric cancers frequently exhibit DNA aneuploidy ([Abad *et al*, 1998](#bib1){ref-type="other"}; [Esteban *et al*, 1999](#bib9){ref-type="other"}; [Imai *et al*, 1999](#bib14){ref-type="other"}; [Russo *et al*, 2000](#bib24){ref-type="other"}; [Tanaka *et al*, 2001](#bib33){ref-type="other"}).

Recently, the *Chfr* (checkpoint with forkhead associated (FHA) and ring finger (RF)) gene, involved in the mitotic stress checkpoint, was cloned and located to chromosome 12q24.33. Its product, CHFR, mediates the delayed entry into metaphase characterised microscopically by delayed chromosomal condensation ([Scolnick and Halazonetis, 2000](#bib28){ref-type="other"}). In addition, CHFR promotes cell survival in response to mitotic stress ([Scolnick and Halazonetis, 2000](#bib28){ref-type="other"}). CHFR possesses an N-terminal FHA domain, a central RF domain and a C-terminal cysteine-rich (CR) region ([Scolnick and Halazonetis, 2000](#bib28){ref-type="other"}). Based on functional analysis of *Chfr* deletion mutants, both the FHA and CR regions are required for its checkpoint function. CHFR also has ubiquitin ligase activity dependent on the RF domain ([Chaturvedi *et al*, 2002](#bib5){ref-type="other"}). Northern blot analysis of *Chfr* using RNA from eight colon, osteosarcoma and neuroblastoma cancer cell lines revealed that *Chfr* expression was absent in three cell lines ([Scolnick and Halazonetis, 2000](#bib28){ref-type="other"}). Loss of *Chfr* expression due to hypermethylation of a CpG island in the promoter region has been observed in tumour cell lines and primary cancers of the lung, oesophagus and colon ([Mizuno *et al*, 2002](#bib22){ref-type="other"}; [Shibata *et al*, 2002](#bib29){ref-type="other"}; [Corn *et al*, 2003](#bib6){ref-type="other"}; [Toyota *et al*, 2003](#bib34){ref-type="other"}). Thus, it is possible that *Chfr* promoter hypermethylation is also involved in gastric carcinogenesis.

As promoter hypermethylation of tumour suppressor or tumour-related genes are not always cancer specific, the significance of promoter methylation status can vary among different genes ([Waki *et al*, 2003a](#bib35){ref-type="other"}, [2003b](#bib36){ref-type="other"}). In the present study, we investigated *Chfr* promoter methylation status in gastric cancer cell lines, primary gastric cancers and corresponding non-neoplastic gastric epithelia, as well as in non-neoplastic gastric epithelia of noncancer-bearing stomachs to clarify both the significance and cancer specificity of *Chfr* promoter hypermethylation in gastric carcinogenesis.

MATERIALS AND METHODS
=====================

Gastric cancer cell lines
-------------------------

In all, 10 gastric cancer cell lines with variable histologies were used in our study and were cultured under appropriate conditions in our laboratory: MKN1, an adenosquamous cell carcinoma; MKN7, a well-differentiated adenocarcinoma; MKN28 and MKN74, moderately differentiated adenocarcinomas; MKN45 and KWS-I, poorly differentiated adenocarcinomas; KATO-III, a signet-ring cell carcinoma; TSG11, a hepatoid carcinoma; and ECC10 and ECC12, endocrine cell carcinomas.

Primary gastric cancers
-----------------------

In all, 71 pairs of gastric cancers (40 differentiated and 31 undifferentiated carcinomas; 15 early stage and 56 advanced stage) and corresponding non-neoplastic gastric mucosa were surgically obtained from 71 patients. Tissue samples were immediately frozen and stored at −80°C until analysis. All patients received a median of 36.7 months of follow-up care (range, 1--77 months).

Autopsy samples
---------------

Non-neoplastic gastric mucosa samples from noncancer-bearing stomachs were obtained from 34 autopsies. The autopsies consisted of 21 males and 13 females, ranging in age from 0.7 to 87 years (mean, 56 years). For most autopsies, tissue samples were obtained from the upper, middle and lower portions of the stomach. A total of 91 specimens were obtained, frozen and stored at −80°C until analysis.

DNA and RNA extraction
----------------------

DNA was extracted from the 10 gastric carcinoma cell lines, 71 primary gastric cancers and their corresponding non-neoplastic gastric mucosa, and 91 non-neoplastic gastric mucosa from autopsies using SepaGene (Sanko-Junyaku, Tokyo, Japan). Total RNA was isolated from the 10 gastric carcinoma cell lines using TRIZOL reagent (Gibco BRL, Life Technologies, Gaithersburg, MD, USA).

Bisulfite modification and methylation-specific polymerase chain reaction (MSP)
-------------------------------------------------------------------------------

Sodium bisulphite treatment of DNA converts all unmethylated cytosines to uracils, but leaves methylated cytosines unaffected. Briefly, 2 *μ*g aliquots of genomic DNA were denatured with sodium hydroxide and modified by sodium bisulphite. Samples were then purified using Wizard DNA purification resin (Promega, Madison, WI, USA), treated with NaOH, recovered in ethanol and resuspended in 30 *μ*l distilled water. Amplification was carried out in a 20 *μ*l reaction volume containing 2 *μ*l GeneAmp PCR Gold Buffer (PE Applied Biosystems, Foster City, CA, USA), 1.0 m[M]{.smallcaps} MgCl~2~, 1 *μ*l each primer, 0.2 m[M]{.smallcaps} dNTPs and 1 U *Taq* polymerase (AmpliTaq Gold DNA Polymerase, PE Applied Biosystems). After heating at 94°C for 10 min, PCR was performed in a thermal cycler (GeneAmp 2400, PE Applied Biosystems) for 35 cycles of denaturation at 94°C for 30 s, annealing at 54°C for 60 s and extension at 72°C for 60 s, followed by a final 7-min extension at 72°C. A positive control (Sss-I methylase-treated DNA) and negative control (distilled water without DNA) were included in each amplification. The PCR products were separated on 6% nondenaturing polyacrylamide gels. The following primer sets were used: Chfr M forward (5′-GTA ATG TTT TTT GAT AGC GGC-3′) and Chfr M reverse (5′-AAT CCC CCT TCG CCG-3′) for methylated *Chfr* sequences; Chfr U forward (5′-GGT TGT AAT GTT TTT TGA TAG TGG T-3′) and Chfr U reverse (5′-CAA ATC CCC CTT CAC CA-3′) for unmethylated *Chfr* sequences ([Corn *et al*, 2003](#bib6){ref-type="other"}).

Reverse transcription--PCR (RT--PCR)
------------------------------------

Isolated RNA was reverse transcribed and amplified using the One-Step RT--PCR System (Gibco BRL). Primer sequences used were: *Chfr* forward (5′-TGG AAC AGT GAT TAA CAA GC-3′) and *Chfr* reverse (5′-AGG TAT CTT TGG TCC CAT GG-3′) for *Chfr*; and *β*-actin forward (5′-AAA TCT GGC ACC ACA CCT T-3′) and *β*-actin reverse (5′-AGC ACT GTG TTG GCG TAC AG-3′) for *β*-actin. RT--PCR products were separated on 3% agarose gels.

5-aza-2′-deoxycytidine (5-aza-dC) treatment
-------------------------------------------

To examine the restoration of *Chfr* expression, two cell lines (MKN1 and KATO-III) were incubated for 96 h with 0.2 or 1 *μ*[M]{.smallcaps} 5-aza-dC (Sigma), and then harvested for RNA extraction and RT--PCR.

Preparation of MSP-positive control
-----------------------------------

Sss-I methylase (New England BioLabs, Inc., Beverly, MA, USA) was used to methylate 100 *μ*g peripheral blood DNA, which was modified by sodium bisulphite as described above.

Statistical analysis
--------------------

Statistical comparisons were performed using Fisher\'s exact test, with *P*\<0.05 considered statistically significant. Survival analysis was performed using a Kaplan--Meier curve with a log-rank test.

RESULTS
=======

Hypermethylation and expression of *Chfr* in gastric cancer cell lines
----------------------------------------------------------------------

*Chfr* promoter hypermethylation was observed in two (MKN1 and KATO-III) of the 10 cell lines tested ([Figure 1](#fig1){ref-type="fig"}Figure 1Methylation-specific polymerase chain reaction (**A** and **B**), RT--PCR (**C** and **D**) and comparison of *Chfr* mRNA expression before (−) and after (+) 5 aza-dC treatment (**E**) in gastric cancer cell lines. (**A**) *Chfr*-methylated-sequence-specific PCR and (**B**) *Chfr*-unmethylated-sequence-specific PCR. Methylated *Chfr* product is present in lanes 1 and 6 (**A**), while demethylated *Chfr* product is present in all lanes except lanes 1 and 6 (**B**). (**C**) *Chfr* RT--PCR and (**D**) *β*-actin RT--PCR (internal control). *Chfr* product is absent in lanes 1 and 6 (**C**). *β*-actin mRNA is present in all lanes (**D**). Lanes: 1, MKN1; 2, MKN7; 3, MKN28; 4, MKN45; 5, MKN74; 6, KATO-III; 7, KWS-I; 8, TSG11; 9, ECC10; 10, ECC12; P, positive control; DW, distilled water; and SM, size marker. (**E**) Treatment with 5 aza-dC restores *Chfr* mRNA expression in KATO-III, but does not affect *Chfr* expression levels in MKN45.). The remaining cells lines (MKN7, MKN28, MKN45, MKN74, KWS-I, TSG11, ECC10 and ECC12) contained unmethylated *Chfr* alleles and expressed abundant *Chfr* mRNA. MKN1 and KATO-III exhibited loss of *Chfr* expression ([Figure 1](#fig1){ref-type="fig"}), which was restored after treatment with 5-aza-dC ([Figure 1](#fig1){ref-type="fig"}). Thus, promoter methylation status of *Chfr* directly correlated with expression.

Hypermethylation of *Chfr* in primary gastric cancers, corresponding non-neoplastic gastric mucosa and autopsy samples
----------------------------------------------------------------------------------------------------------------------

Hypermethylation of *Chfr* was detected in 35% (25 of 71) of primary gastric cancers but only in 5% (four of 71) of the corresponding non-neoplastic gastric mucosa ([Figure 2](#fig2){ref-type="fig"}Figure 2Methylation-specific polymerase chain reaction of primary gastric cancers (T) and their corresponding non-neoplastic gastric mucosa (N). M, *Chfr*-methylated-sequence-specific PCR; U, *Chf-* unmethylated-sequence-specific PCR; P, positive control; DW, distilled water; and SM, size marker. Methylated *Chfr* is present in primary gastric cancers (M123, M137, M145, M157, M245), whereas non-neoplastic gastric mucosa samples do not exhibit methylated *Chfr*.). *Chfr* hypermethylation was observed in only one (1%) of the 91 autopsy samples. This single sample showing *Chfr* hypermethylation was obtained from the lower portion of the stomach from an 82-year-old-male patient with Parkinson\'s disease.

Correlation between *Chfr* promoter hypermethylation and clinicopathological parameters
---------------------------------------------------------------------------------------

*Chfr* hypermethylation occurred at a similar frequency in early and advanced gastric cancers, and no significant correlations between *Chfr* promoter methylation status and clinicopathological factors were observed ([Table 1](#tbl1){ref-type="table"} Table 1Correlation between *Chfr* promoter methylation status and clinicopathological characteristics in gastric cancer patients **Promoter methylation status**  **MethylatedUnmethylated** [^1]). Methylation status did not significantly influence event-free survival rate, as analysed by Kaplan--Meier curve with log-rank test and the Breslow--Gehan--Wilcoxon test (data not shown).

DISCUSSION
==========

Although CIN is one of the most frequently recognised phenomenon in gastric cancer ([Abad *et al*, 1998](#bib1){ref-type="other"}; [Esteban *et al*, 1999](#bib9){ref-type="other"}; [Russo *et al*, 2000](#bib24){ref-type="other"}), the mitotic checkpoint genes *hsMAD2* and *hBUB1* are rarely mutated in gastric and other types of human malignancy ([Imai *et al*, 1999](#bib14){ref-type="other"}; [Tanaka *et al*, 2001](#bib33){ref-type="other"}). Checkpoints upstream of the spindle checkpoint that delays chromosome condensation in response to mitotic stress are regulated by CHFR. Normal primary cells and cancer cell lines that express CHFR exhibit delayed entry into metaphase after treatment with microtubule inhibitors ([Scolnick and Halazonetis, 2000](#bib28){ref-type="other"}). In contrast, cancer cell lines that lack CHFR enter metaphase without delay, with ectopic expression of CHFR necessary and sufficient to restore cell-cycle delay ([Scolnick and Halazonetis, 2000](#bib28){ref-type="other"}). Recent studies of human tumours have shown that *Chfr* inactivation can be due to hypermethylation of CpGs in the promoter region ([Mizuno *et al*, 2002](#bib22){ref-type="other"}; [Shibata *et al*, 2002](#bib29){ref-type="other"}). However, whether *Chfr* promoter hypermethylation is involved in gastric cancer has not yet been determined.

In the present study, we showed that *Chfr* promoter hypermethylation was present in two of 10 (20%) gastric cancer cell lines and in 25 of 71 (35%) primary gastric cancers. As for non-neoplastic gastric epithelia, 5% (four of 71) of samples from cancer-bearing and 1% (one of 91) from noncancer-bearing stomachs exhibited *Chfr* promoter hypermethylation. We have shown that many tumour suppressor and tumour-related genes, such as *APC, DAP-kinase, DCC, E-cadherin, hMLH1, p16, RASSF1A* and *RUNX3*, exhibit promoter hypermethylation in both neoplastic and non-neoplastic gastric epithelia at variable frequencies ([Tamura, 2004](#bib31){ref-type="other"}). While *GSTP1* and *PTEN* promoters remained unmethylated in both neoplastic and non-neoplastic gastric epithelia ([Sato *et al*, 2002](#bib25){ref-type="other"}; [Tamura, 2004](#bib31){ref-type="other"}), *TSLC1* promoter hypermethylation is highly cancer specific, but is observed at only a low frequency in gastric cancer ([Honda *et al*, 2002](#bib13){ref-type="other"}).

Methylation generally increases with age in tissue-specific manner for different genes ([Waki *et al*, 2003b](#bib36){ref-type="other"}). In the present study, the only sample of non-neoplastic gastric mucosa that exhibited *Chfr* hypermethylation was obtained from the noncancer-bearing stomach of an 82-year-old male patient. In contrast, *Chfr* hypermethylation was present in cancer-bearing stomachs from patients from 66 years of age. Based on these observations, it appears that age-related *Chfr* hypermethylation may constitute a general defect where individuals may become predisposed to the development of gastric cancer. The cancer specificity of hypermethylation of a particular promoter can depend on the CpG site examined ([Satoh *et al*, 2002](#bib26){ref-type="other"}). Our present study revealed that *Chfr* promoter hypermethylation appears to be one of the most cancer-specific alterations among the various examples of tumour suppressor and tumour-related gene hypermethylation reported to date ([Tamura, 2004](#bib31){ref-type="other"}).

While *Chfr* promoter hypermethylation is a relatively infrequent non-neoplastic gastric epithelia, it occurs at similar frequencies in early and advanced gastric cancers. This suggests that *Chfr* promoter hypermethylation may be an early event in gastric carcinogenesis. DNA aneuploidy has been observed in 50--71% of gastric cancers and correlates with poor prognosis ([Abad *et al*, 1998](#bib1){ref-type="other"}; [Esteban *et al*, 1999](#bib9){ref-type="other"}; [Russo *et al*, 2000](#bib24){ref-type="other"}). In the present study, we failed to find a statistically significant correlation between *Chfr* hypermethylation and gastric cancer patient survival. Nonetheless, our results did display a tendency towards a worse prognosis in patients with tumours that displayed *Chfr* hypermethylation. Owing to the lack of a significant correlation between *Chfr* methylation status and prognosis, and the relatively low frequency of *Chfr* hypermethylation compared to that of DNA aneuploidy, other gene(s) and/or mechanism(s) are likely to also contribute to CIN in gastric cancer.

In conclusion, *Chfr* promoter hypermethylation frequently occurs as an early event of gastric carcinogenesis. Owing to its cancer specificity, detection of *Chfr* promoter methylation could be useful as a molecular diagnostic marker for gastric cancer.

[^1]: NS=not significant by Fisher\'s exact probability test. *Chfr*=checkpoint with forkhead associated and ring finger.
